NEW YORK (GenomeWeb) – Agilent Technologies this week announced that its board has approved a quarterly dividend of $.13 per share of common stock, payable on Oct. 25 to all shareholders of record as of the close of business on Oct. 3.

Edico Genome announced this week that its DRAGEN Bio-IT Platform is now available on Illumina's BaseSpace Sequence Hub. Users can now run DRAGEN instances to enhance the accuracy and speed of their secondary analysis of next-generation sequencing data, the company said.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.